Skip Nav Destination
Issues
1 April 2012
-
Cover Image
Cover Image
High-level EGFR gene amplification can be retained in glioblastoma stem-like cell lines established and propagated without recombinant EGF. In contrast, high-level amplification is lost in parallel cell lines from the same tumors established with EGF supplementation. Cell lines with high-level EGFR amplification produce highly aggressive xenograft tumors in the brains of nude mice, retaining the EGFR amplification as shown in the cover figure, whereas counterpart cell lines, lacking high-level amplification, are either nontumorigenic or grow significantly more slowly in vivo. For details, see the article by Schulte and colleagues on page 1901 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Issue Sections
Highlights
CCR Translations
CCR New Strategies
Statistics in Clinical Cancer Research
CCR Drug Updates
Molecular Pathways
Human Cancer Biology
Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors
Carlo Visco; Francesco Maura; Giacomo Tuana; Luca Agnelli; Marta Lionetti; Sonia Fabris; Elisabetta Novella; Ilaria Giaretta; Gianluigi Reda; Wilma Barcellini; Luca Baldini; Antonino Neri; Francesco Rodeghiero; Agostino Cortelezzi
MAPKAP Kinase 2 Overexpression Influences Prognosis in Gastrointestinal Stromal Tumors and Associates with Copy Number Variations on Chromosome 1 and Expression of p38 MAP Kinase and ETV1
Peter Birner; Andrea Beer; Ursula Vinatzer; Susanne Stary; Romana Höftberger; Nadine Nirtl; Fritz Wrba; Berthold Streubel; Sebastian F. Schoppmann
Protein Kinase CK2 Protects Multiple Myeloma Cells from ER Stress–Induced Apoptosis and from the Cytotoxic Effect of HSP90 Inhibition through Regulation of the Unfolded Protein Response
Sabrina Manni; Alessandra Brancalion; Laura Quotti Tubi; Anna Colpo; Laura Pavan; Anna Cabrelle; Elisa Ave; Fortunato Zaffino; Giovanni Di Maira; Maria Ruzzene; Fausto Adami; Renato Zambello; Maria Rita Pitari; Pierfrancesco Tassone; Lorenzo A. Pinna; Carmela Gurrieri; Gianpietro Semenzato; Francesco Piazza
Glioblastoma Stem–like Cell Lines with Either Maintenance or Loss of High-Level EGFR Amplification, Generated via Modulation of Ligand Concentration
Alexander Schulte; Hauke S. Günther; Tobias Martens; Svenja Zapf; Sabine Riethdorf; Clemens Wülfing; Malgorzata Stoupiec; Manfred Westphal; Katrin Lamszus
Cancer Therapy: Preclinical
ON 01910.Na Is Selectively Cytotoxic for Chronic Lymphocytic Leukemia Cells through a Dual Mechanism of Action Involving PI3K/AKT Inhibition and Induction of Oxidative Stress
Colby M. Chapman; Xiameng Sun; Mark Roschewski; Georg Aue; Mohamed Farooqui; Lawrence Stennett; Federica Gibellini; Diane Arthur; Patricia Pérez-Galán; Adrian Wiestner
Imaging, Diagnosis, Prognosis
Copy Number Gain of 1q25 Predicts Poor Progression-Free Survival for Pediatric Intracranial Ependymomas and Enables Patient Risk Stratification: A Prospective European Clinical Trial Cohort Analysis on Behalf of the Children's Cancer Leukaemia Group (CCLG), Société Française d'Oncologie Pédiatrique (SFOP), and International Society for Pediatric Oncology (SIOP)
John-Paul Kilday; Biswaroop Mitra; Caroline Domerg; Jennifer Ward; Felipe Andreiuolo; Teresa Osteso-Ibanez; Audrey Mauguen; Pascale Varlet; Marie-Cecile Le Deley; James Lowe; David W. Ellison; Richard J. Gilbertson; Beth Coyle; Jacques Grill; Richard G. Grundy
A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma
Idoia Garcia; Gemma Mayol; José Ríos; Gema Domenech; Nai-Kong V. Cheung; André Oberthuer; Matthias Fischer; John M. Maris; Garrett M. Brodeur; Barbara Hero; Eva Rodríguez; Mariona Suñol; Patricia Galvan; Carmen de Torres; Jaume Mora; Cinzia Lavarino
18F-FDG-PET/CT Imaging as an Early Survival Predictor in Patients with Primary High-Grade Soft Tissue Sarcomas Undergoing Neoadjuvant Therapy
Ken Herrmann; Matthias R. Benz; Johannes Czernin; Martin S. Allen-Auerbach; William D. Tap; Sarah M. Dry; Tibor Schuster; Jeff J. Eckardt; Michael E. Phelps; Wolfgang A. Weber; Fritz C. Eilber
A Panel of Four miRNAs Accurately Differentiates Malignant from Benign Indeterminate Thyroid Lesions on Fine Needle Aspiration
Xavier M. Keutgen; Filippo Filicori; Michael J. Crowley; Yongchun Wang; Theresa Scognamiglio; Rana Hoda; Daniel Buitrago; David Cooper; Martha A. Zeiger; Rasa Zarnegar; Olivier Elemento; Thomas J. Fahey, III
Cancer Therapy: Clinical
Phase I Study of Rigosertib, an Inhibitor of the Phosphatidylinositol 3-Kinase and Polo-like Kinase 1 Pathways, Combined with Gemcitabine in Patients with Solid Tumors and Pancreatic Cancer
Wen Wee Ma; Wells A. Messersmith; Grace K. Dy; Colin D. Weekes; Amy Whitworth; Chen Ren; Manoj Maniar; Francois Wilhelm; S. Gail Eckhardt; Alex A. Adjei; Antonio Jimeno
Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements
D. Neil Hayes; Amy S. Lucas; Tawee Tanvetyanon; Monika K. Krzyzanowska; Christine H. Chung; Barbara A. Murphy; Jill Gilbert; Ranee Mehra; Dominic T. Moore; Arif Sheikh; Janelle Hoskins; Michele C. Hayward; Ni Zhao; Wendi O'Connor; Karen E. Weck; Roger B. Cohen; Ezra E.W. Cohen
Phase I/II Trial of Carboplatin and Paclitaxel Chemotherapy in Combination with Intravenous Oncolytic Reovirus in Patients with Advanced Malignancies
Eleni M. Karapanagiotou; Victoria Roulstone; Katie Twigger; Mercel Ball; MaryAnne Tanay; Chris Nutting; Kate Newbold; Martin E. Gore; James Larkin; Konstantinos N. Syrigos; Matt Coffey; Brad Thompson; Karl Mettinger; Richard G. Vile; Hardev S. Pandha; Geoff D. Hall; Alan A. Melcher; John Chester; Kevin J. Harrington
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Cody J. Peer; Tristan M. Sissung; AeRang Kim; Lokesh Jain; Sukyung Woo; Erin R. Gardner; C. Tyler Kirkland; Sarah M. Troutman; Bevin C. English; Emily D. Richardson; Joel Federspiel; David Venzon; William Dahut; Elise Kohn; Shivaani Kummar; Robert Yarchoan; Giuseppe Giaccone; Brigitte Widemann; William D. Figg
Predictive Biomarkers and Personalized Medicine
Tumor Hypoxia Predicts Biochemical Failure following Radiotherapy for Clinically Localized Prostate Cancer
Michael Milosevic; Padraig Warde; Cynthia Ménard; Peter Chung; Ants Toi; Adrian Ishkanian; Michael McLean; Melania Pintilie; Jenna Sykes; Mary Gospodarowicz; Charles Catton; Richard P. Hill; Robert Bristow
Corrections
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.